Study Evaluating Etanercept Treatment of Patients With Ankylosing Spondylitis
Status:
Completed
Trial end date:
2002-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study was to compare the efficacy of etanercept (25 mg, twice
weekly) with that of placebo based on the percentage of patients who achieve the Assessment
in Ankylosing Spondylitis (ASAS) response criteria (ASAS 20%) at week 12.